Hormone Therapy

Oral contraceptive use and hormone therapy were associated with an increased risk for stroke, according to study findings published in Stroke.

Although incidence was low, transgender individuals in Sweden experienced higher CVD incidence compared with cisgender controls from the country’s general population, researchers reported.

Healio and Cardiology Today have compiled the most-read cardiology news of June 2022.

Low income, Medicaid insurance and lack of family support were among the factors associated with transgender and nonbinary youths experiencing delays in receiving puberty blockers or gender-affirming hormones, according to study data.

PHILADELPHIA — In this Healio video exclusive, Gina Lundberg, MD, FACC, provides an overview of the Heart in Diabetes CME conference presentation, titled “CVD in Women, Ischemia Diagnosis and Menopause Hormone Therapy.”

ATLANTA — Adults with growth hormone deficiency have higher health care costs and more comorbidities than those without growth hormone deficiency, according to findings presented at ENDO 2022.

In men with hypogonadism, there was no evidence that testosterone treatments cause short-term or medium-term CV risks, according to a meta-analysis published in The Lancet Healthy Longevity.

For its 20th year in print, Endocrine Today is taking a look back at changes in endocrine gender care.

SAN DIEGO — In this video exclusive, Jonathan D. Leffert, MD, talks with Joshua D. Safer, MD, FACP, FACE, and Vin Tangpricha, MD, PhD about clinical and political challenges in caring for transgender patients.

CHICAGO — Transgender and nonbinary patients continue to face substantial health disparities, many of which are due to “the awkward interface” between them and the health care system, according to Richard E. Greene, MD, MHPE, FACP.